- Home
- ASPI vs TNGX Comparison
ASPI vs TNGX Comparison
Compare ASPI & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASPI
- TNGX
- Stock Information
- Founded
- ASPI 2021
- TNGX 2014
- Country
- ASPI United States
- TNGX United States
- Employees
- ASPI N/A
- TNGX N/A
- Industry
- ASPI Major Chemicals
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- ASPI Industrials
- TNGX Health Care
- Exchange
- ASPI Nasdaq
- TNGX Nasdaq
- Market Cap
- ASPI 653.4M
- TNGX 723.2M
- IPO Year
- ASPI 2022
- TNGX N/A
- Fundamental
- Price
- ASPI $9.26
- TNGX $6.82
- Analyst Decision
- ASPI Strong Buy
- TNGX Strong Buy
- Analyst Count
- ASPI 1
- TNGX 6
- Target Price
- ASPI $11.00
- TNGX $10.00
- AVG Volume (30 Days)
- ASPI 4.5M
- TNGX 1.5M
- Earning Date
- ASPI 08-14-2025
- TNGX 11-05-2025
- Dividend Yield
- ASPI N/A
- TNGX N/A
- EPS Growth
- ASPI N/A
- TNGX N/A
- EPS
- ASPI N/A
- TNGX N/A
- Revenue
- ASPI $4,581,523.00
- TNGX $24,296,000.00
- Revenue This Year
- ASPI $512.64
- TNGX $6.56
- Revenue Next Year
- ASPI $181.15
- TNGX N/A
- P/E Ratio
- ASPI N/A
- TNGX N/A
- Revenue Growth
- ASPI 99.57
- TNGX N/A
- 52 Week Low
- ASPI $2.55
- TNGX $1.03
- 52 Week High
- ASPI $11.68
- TNGX $10.81
- Technical
- Relative Strength Index (RSI)
- ASPI 52.28
- TNGX 52.79
- Support Level
- ASPI $8.13
- TNGX $6.25
- Resistance Level
- ASPI $9.09
- TNGX $6.90
- Average True Range (ATR)
- ASPI 0.66
- TNGX 0.41
- MACD
- ASPI -0.02
- TNGX -0.04
- Stochastic Oscillator
- ASPI 49.37
- TNGX 49.57
About ASPI ASP Isotopes Inc.
ASP Isotopes Inc is a pre-commercial stage advanced materials company dedicated to the development of technology and processes that, if successful, will allow for the production of isotopes that may be used in several industries. The company utilizes technology developed in South Africa over the past 20 years to enrich isotopes of elements or molecules with low atomic masses.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.